Cullinan Therapeutics, Inc. (CGEM)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$22.09-0.32%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CGEM
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | — | — | — | — | 0.0 | 18.9 | 0.0 |
| Operating Expenses & Income | |||||||
| R&D Expenses | 171.5 | 187.4 | 142.9 | 148.2 | 91.9 | 57.8 | 43.2 |
| Operating Income | (221.8) | (241.6) | (196.9) | (191.1) | 144.6 | (68.0) | (60.3) |
| Earnings from Continuing Operations | |||||||
| Interest & Investment Income | 17.5 | 22.2 | 29.7 | 21.6 | 6.6 | 0.5 | 0.9 |
| EBT, Incl. Unusual Items | — | (219.9) | (167.5) | (169.2) | 151.3 | (67.5) | — |
| Income Tax Expense | — | — | 0.1 | (14.1) | 42.1 | 0.0 | — |
| Net Income | |||||||
| Minority Interest | — | — | (0.2) | (1.9) | (2.0) | (1.9) | (7.7) |
| Net Income | (204.7) | (219.9) | (167.4) | (155.1) | 111.2 | (65.6) | (51.8) |
| Per Share | |||||||
| Basic EPS | — | — | — | (3.69) | 2.46 | (1.52) | — |
| Diluted EPS | — | — | — | (3.69) | 2.38 | (1.52) | — |
| Basic Weighted Avg Shares | — | — | — | 41.6 | 45.2 | 43.1 | — |
| Diluted Weighted Avg Shares | — | — | — | 41.6 | 46.6 | 43.1 | — |
| Supplemental | |||||||
| EBITDA | — | (241.3) | (196.6) | (190.8) | 144.7 | (67.9) | (60.3) |
| EBIT | (221.8) | (241.6) | (196.9) | (191.1) | 144.6 | (68.0) | (60.3) |
| Effective Tax Rate | — | — | — | 8.3% | 27.8% | 0.0% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.